Matinas BioPharma Holdings, Inc. (MTNB) Net Income by Year
Matinas BioPharma Holdings, Inc. reported a net loss of $10.3M in fiscal year 2025. This represents an increase of 57.3% from the prior fiscal year. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Matinas BioPharma Holdings, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
MTNB Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
MTNB Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Matinas BioPharma Holdings, Inc. financials
Frequently Asked Questions
What was Matinas BioPharma Holdings, Inc.'s net income in fiscal year 2025?
Matinas BioPharma Holdings, Inc. reported a net loss of $10.3M in fiscal year 2025.
How fast is Matinas BioPharma Holdings, Inc.'s net income growing?
Matinas BioPharma Holdings, Inc. (MTNB) net income rose by 57.3% year over year, from -$24.3M to -$10.3M in fiscal year 2025.
How has Matinas BioPharma Holdings, Inc.'s net income changed over the years?
Across the 13 fiscal years this page covers, Matinas BioPharma Holdings, Inc. (MTNB) net income went from -$3.7M in fiscal year 2013 to -$10.3M in fiscal year 2025.
What was Matinas BioPharma Holdings, Inc.'s net income in the most recent quarter?
Matinas BioPharma Holdings, Inc. (MTNB) reported -$1.3M in net income in Q2 2026. This represents an increase of 74.7% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Matinas BioPharma Holdings, Inc. (MTNB) reported on that line in every period on record.